Press Release and Presentation On Financials

Jubilant Pharmova reported FY26 revenue of Rs. 8,280 Cr (up 14% YoY) and EBITDA of Rs. 1,326 Cr (up 8%). EBITDA margins declined 99 bps to 15.9% due to temporary shutdown of the Montreal CDMO facility for FDA remediation, affecting the radiopharma and CDMO segments. Normalised PAT grew 7% to Rs. 442 Cr. The company proposed a dividend of Rs. 5 per share. Key growth highlights include: CDMO Sterile Injectables revenue grew 38% to Rs. 1,755 Cr driven by Line 3 ramp-up at Spokane; Radiopharma revenue grew 10% to Rs. 1,178 Cr; one of the world's largest oncology products was onboarded on Line 3 (commercial production expected late FY27). Management stated that EBITDA margins will strengthen from H2'FY27 onwards as Montreal production stabilises and higher depreciation from new lines gets offset by volume ramp. Net Debt/EBITDA stood at 1.3x at end of FY26. Vision 2030 targets aspirational revenue of Rs. 13,500 Cr with 23-25% EBITDA margin.